ClinicalTrials.gg
CompletedNCT03934684Updated May 11, 2026Results posted

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

A Phase 4 interventional study of Drug: Carfilzomib + Dexamethasone and Drug: Carfilzomib + Lenalidomide + Dexamethasone in Relapsed Refractory Multiple Myeloma, sponsored by Amgen. Completed at 17 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.

Enrollment
27th of 113
101 · median 54
Started
2019
with 11 others
Phase 4
2 of 113
1 open now
Registered
82nd of 113
by date
Lead sponsor
21 of 113
Amgen

Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 27th largest by enrollment, is one of 12 that started in 2019, is one of 2 in phase 4, and was the 82nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carfilzomib

carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing carfilzomib in Multiple Myeloma, or all of them as a file.
02

Study summary

To characterize safety associated with the use of Kyprolis under the locally approved label.

Read the detailed description

Kyprolis® (K; carfilzomib) was approved in India on 17 January 2017 as a prescription medication in combination with dexamethasone (Kd) or with lenalidomide (Revlimid®) plus dexamethasone (KRd) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) following 1 to 3 prior lines of therapy.

This non-comparative, interventional phase 4 study is designed to fulfil the post-marketing requirement to assess safety, tolerability, and efficacy of Kyprolis on Indian subjects with RRMM as per the locally approved label.

03

Conditions studied

  • Relapsed Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented RRMM after last treatment. is defined as meeting 1 or more of the following: Nonresponsive to most recent therapy (stable disease [SD] or progressive disease [PD]) while on treatment, or Disease progression within 60 days of discontinuation from the most recent therapy.
  • Eligible to receive Kyprolis per the locally approved label.
  • (ECOG) performance status of 0 to 2.
  • Adequate hepatic function within 28 days prior to enrollment: \< 1.5 times the (ULN); (AST) and alanine aminotransferase (ALT) \< 2.5 times the ULN.
  • (ANC) ≥ 1.0 x 10\^9 /L within 28 days prior to enrollment. (Screening ANC should be independent of granulocyte- and granulocyte macrophage-colony stimulating factor support for at least 1 week and of pegylated granulocyte stimulating factor for ≥ 2 weeks).
  • ≥ 80 g/L within 28 days prior to enrollment. Subjects should not have received red blood cell (RBC) transfusions for at least 7 days prior to obtaining the screening hemoglobin.
  • count ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if myeloma involvement in the bone marrow is ≥ 50%) within 28 days prior to enrollment. Subjects should not have received platelet transfusions for at least 7 days prior to obtaining the screening platelet count.
  • Adequate renal function within 28 days prior to enrollment (either measured or calculated using a standard formula such as the Cockcroft and Gault): calculated or measured (CrCl) of ≥ 50 mL/min for subjects receiving KRd; calculated or measured CrCl of ≥ 15 mL/min for subjects receiving Kd.
  • ≥ 40% as assessed by transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA).
  • Females of (FCBP) must have a negative serum pregnancy test within the 10 to 14 days prior to enrollment and a negative urine pregnancy test within the 24 hours prior to day 1 of each cycle prior to dosing.
  • Subject or legally acceptable representative has provided /assent prior to initiation of any study specific activities/procedures.

Exclusion criteria

Exclusion Criteria:

  • Waldenström macroglobulinemia.
  • Plasma cell leukemia (> 2.0 x 10\^9/L circulating plasma cells by standard differentials).
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Myelodysplastic síndrome.
  • Primary amyloidosis (subjects with multiple myeloma with asymptomatic deposition of amyloid plaques found on would be eligible if all other criteria are met).
  • History of other within the past 5 years, with the following exception[s]: Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately treated cervical carcinoma in situ without evidence of disease. Adequately treated breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cáncer. Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
  • Known immediate or delayed reaction to Captisol (a cyclodextrin derivative used to solubilize Kyprolis).
  • to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs.
  • Intolerance to hydration.
  • Active congestive heart failure ( [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, echocardiogram (ECHO) abnormalities, screening with interval (QTc) of > 470 msec, pericardial disease, or myocardial infarction within 4 months prior to enrollment.
  • Infiltrative pulmonary disease and/or known pulmonary hypertension.
  • Active infection within 14 days prior to enrollment requiring systemic antibiotics, antiviral (except antiviral therapy directed at ) or antifungal agents. Such infections must be fully resolved prior to initiating study treatment.
  • Pleural effusions requiring thoracentesis within 14 days prior to enrollment.
  • Ascites requiring paracentesis within 14 days prior to enrollment.
  • Uncontrolled hypertension, defined as an average systolic blood pressure > 159 mmHg or diastolic > 99 mm/Hg despite optimal treatment (measured following European Society of Hypertension/European Society of Cardiology [ESH/ESC] 2013 guidelines.
  • Active hepatitis B virus (HBV) infection. Subjects with positive hepatitis B surface antigen (HBsAg) or core antibody (anti-HBc) that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed. Subjects with known history or resolved infection (negative for HBsAg but positive for antibodies to surface antigen, and/or core antigen) must be screened with HBV DNA levels. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (hepatitis B surface antibody [anti-HBs] positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA.
  • Known (HIV) infection, infection (subjects with hepatitis C that achieve a sustained virologic response following antiviral therapy are allowed).
  • Ongoing .
  • Subjects with grade 3 or worse neuropathy within 14 days prior to enrollment.
  • Antitumor therapy (eg, chemotherapy, immunotherapy, antibody therapy) or agent within 28 days before enrollment or not recovered from any acute toxicity.
  • Subjects on therapy for graft versus host disease, even if it has resolved.
  • therapy within 14 days before first dose that exceeds a cumulative dose of 160 mg or dexamethasone or equivalent dose of other corticosteroids.
  • Focal radiation therapy within 7 days before enrollment. Radiation therapy to an extended field involving significant volume of bone marrow within 28 days prior to enrollment (ie, prior radiation must have been to less than 30% of the bone marrow).
  • stem cell transplant less than 100 days prior to enrollment.
  • Prior treatment with Kyprolis (carfilzomib).
  • Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
  • Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment, during any breaks (interruptions) in the treatment, and for an additional 30 days after the last dose of Kyprolis. Females of should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test.
  • Female subjects of childbearing potential unwilling to use 1 highly effective method of during treatment, during any breaks (interruptions) in the treatment, and for an additional 30 days after the last dose of Kyprolis.

NOTE: Female subjects of childbearing potential being treated with lenalidomide must agree to use 2 methods of contraception for at least 28 days before starting treatment, during treatment, during any breaks (interruptions) in the treatment, and for an additional 30 days after the last dose of treatment.

  • Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 90 days after the last dose of Kyprolis.

NOTE: Male subjects being treated with lenalidomide must agree to use a male condom with spermicide even if they have undergone a successful vasectomy.

  • Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 90 days after the last dose of Kyprolis.
  • Male subjects unwilling to abstain from donating sperm during treatment and for an additional 90 days after the last dose of Kyprolis.
  • Subject likely to not be available to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Active hepatitis B virus (HBV) infection. Subjects with positive hepatitis B surface antigen (HBsAg) or core antibody (anti-HBc) that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed. Subjects with known history or resolved infection (negative for HBsAg but positive for antibodies to surface antigen, and/or core antigen) must be screened with HBV DNA levels. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (hepatitis B surface antibody [anti-HBs] positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Carfilzomib + Dexamethasone

    Drug: Carfilzomib + Dexamethasone * Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter. * Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression

    Drug: Drug: Carfilzomib + Dexamethasone

  • Experimental
    Carfilzomib+Lenalidomide+Dexamethasone

    Drug: Carfilzomib + Lenalidomide + Dexamethasone * Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted. * Lenalidomide 25 mg is taken orally on days 1 to 21. * Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination.

    Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone

Interventions

  • DrugDrug: Carfilzomib + Dexamethasone

    Drug pages: Carfilzomib · Dexamethasone

    Drug: Carfilzomib + Dexamethasone * Carfilzomib will be administered as a 30-minute infusion. * Dexamethasone will be taken by mouth or intravenously.

    Also known as: Kyprolis

  • DrugDrug: Carfilzomib + Lenalidomide + Dexamethasone

    Drug pages: Carfilzomib · Lenalidomide · Dexamethasone

    Drug: Carfilzomib + Lenalidomide + Dexamethasone * Carfilzomib will be administered as a 10 minute infusion. * Lenalidomide will be taken orally. * Dexamethasone will be taken by mouth or intravenously.

    Also known as: Kyprolis

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    A TEAE was any untoward medical occurrence in a clinical trial participant after the first dose of investigational product (IP) irrespective of a causal relationship with the IP. TEAEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03. Any clinically significant laboratory changes over time were recorded as TEAEs.

    Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

  2. Number of Participants Who Experienced Serious TEAEs

    A serious TEAE was any untoward medical occurrence in a clinical trial participant after first dose of IP irrespective of a causal relationship with the IP(s), that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.

    Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

Secondary outcomes

  1. Progression Free Survival (PFS) as Per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC)

    PFS was defined as the time from first dose of IP until the earliest date of disease progression (PD) or death due to any cause. PD was per IMWG-URC, with progression assessments at intervals as per local standard of care. PD: increase of 25% from lowest response value in serum M-component and/or urine M-component and/or only in participants without measurable serum and urine M protein levels: the difference between involved and uninvolved free light chain (FLC) levels and/or only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow (BM) plasma cell percentage; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia. Medians were estimated using the Kaplan-Meier method. Corresponding 95% confidence intervals (CIs) were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months

  2. Overall Response Rate (ORR) as Per IMWG-URC

    ORR was defined as the percentage of participants for whom the best overall response was a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as determined by the IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. The ORR 95% CIs were estimated using the Clopper-Pearson method.

    Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

  3. Clinical Benefit Rate (CBR) as Per IMWG-URC

    CBR was defined as the percentage of participants with either the best overall response of sCR, CR, VGPR, PR, and minimal response (MR) as determined by the IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in BM. sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. MR: ≥ 25% but ≤ 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50% to 89%. The CBR 95% CIs were estimated using the Clopper-Pearson method.

    Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

  4. Time to Response (TTR) as Per IMWG-URC

    TTR was defined as the time from first dose date to the earliest date when confirmed sCR, CR, VGPR, or PR was first achieved. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in BM. sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. Medians were estimated using the Kaplan-Meier method.

    Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

  5. Duration of Response (DOR) as Per IMWG-URC

    DOR was defined as the time from first evidence of PR or better as per IMWG-URC to the earliest of PD or death due to any cause for participants with a best response of PR or better. PD: increase of 25% from lowest response value in serum M-component and/or urine M-component and/or only in participants without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels and/or only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia. Medians were estimated using the Kaplan-Meier method. Corresponding 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

    Time frame: From enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months

07

Results

Posted Jan 2, 2024

Participant flow

101 participants were enrolled at 15 centers in India between September 2019 and June 2025.

Participant flow — Overall Study
MilestoneCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Started4952
Completed174
Not completed3248
Withdrew: Withdrawal by subject78
Withdrew: Lost to follow-up25
Withdrew: Death22
Withdrew: Discontinuation of carfilzomib2133

Outcome measures

PrimaryNumber of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

A TEAE was any untoward medical occurrence in a clinical trial participant after the first dose of investigational product (IP) irrespective of a causal relationship with the IP. TEAEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03. Any clinically significant laboratory changes over time were recorded as TEAEs.

Time frame:
From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
ParticipantsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)4645
PrimaryNumber of Participants Who Experienced Serious TEAEs

A serious TEAE was any untoward medical occurrence in a clinical trial participant after first dose of IP irrespective of a causal relationship with the IP(s), that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.

Time frame:
From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Serious TEAEs
ParticipantsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Number of Participants Who Experienced Serious TEAEs1120
SecondaryProgression Free Survival (PFS) as Per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC)

PFS was defined as the time from first dose of IP until the earliest date of disease progression (PD) or death due to any cause. PD was per IMWG-URC, with progression assessments at intervals as per local standard of care. PD: increase of 25% from lowest response value in serum M-component and/or urine M-component and/or only in participants without measurable serum and urine M protein levels: the difference between involved and uninvolved free light chain (FLC) levels and/or only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow (BM) plasma cell percentage; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia. Medians were estimated using the Kaplan-Meier method. Corresponding 95% confidence intervals (CIs) were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Median · months
Progression Free Survival (PFS) as Per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC)
monthsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Progression Free Survival (PFS) as Per International Myeloma Working Group-Uniform Response Criteria (IMWG-URC)NA (14.7 to NA)NA (13.1 to NA)
SecondaryOverall Response Rate (ORR) as Per IMWG-URC

ORR was defined as the percentage of participants for whom the best overall response was a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as determined by the IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. The ORR 95% CIs were estimated using the Clopper-Pearson method.

Time frame:
From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) as Per IMWG-URC
percentage of participantsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Overall Response Rate (ORR) as Per IMWG-URC59.2 (44.2 to 73.0)53.8 (39.5 to 67.8)
SecondaryClinical Benefit Rate (CBR) as Per IMWG-URC

CBR was defined as the percentage of participants with either the best overall response of sCR, CR, VGPR, PR, and minimal response (MR) as determined by the IMWG-URC. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in BM. sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. MR: ≥ 25% but ≤ 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50% to 89%. The CBR 95% CIs were estimated using the Clopper-Pearson method.

Time frame:
From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) as Per IMWG-URC
percentage of participantsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Clinical Benefit Rate (CBR) as Per IMWG-URC63.3 (48.3 to 76.6)57.7 (43.2 to 71.3)
SecondaryTime to Response (TTR) as Per IMWG-URC

TTR was defined as the time from first dose date to the earliest date when confirmed sCR, CR, VGPR, or PR was first achieved. CR: negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in BM. sCR: CR and normal serum free light chain ratio and no clonal cells in BM by immunohistochemistry. VGPR: Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-hours). PR: ≥ 50% reduction of serum M-protein and reduction in 24-hours urinary M-protein by ≥ 90% or to \< 200 mg/24-hours. Medians were estimated using the Kaplan-Meier method.

Time frame:
From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Median · months
Time to Response (TTR) as Per IMWG-URC
monthsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Time to Response (TTR) as Per IMWG-URC2.8 (1 to 10)2.6 (1 to 8)
SecondaryDuration of Response (DOR) as Per IMWG-URC

DOR was defined as the time from first evidence of PR or better as per IMWG-URC to the earliest of PD or death due to any cause for participants with a best response of PR or better. PD: increase of 25% from lowest response value in serum M-component and/or urine M-component and/or only in participants without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels and/or only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cell percentage; definite development of new bone lesions or soft tissue plasmacytomas; development of hypercalcemia. Medians were estimated using the Kaplan-Meier method. Corresponding 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Time frame:
From enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months
Reported as:
Median · months
Duration of Response (DOR) as Per IMWG-URC
monthsCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
Duration of Response (DOR) as Per IMWG-URCNA (11.9 to NA)NA (12.4 to NA)

Adverse events

Collected over For all-cause mortality reporting, from enrollment until the end of trial or death date, whichever occurred earlier; median (min, max) time on trial was 8.7 (0.1, 37.2) months. For Adverse Event reporting, from the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib, Lenalidomide and Dexamethasone (KRd)2/49 (4.1%)11/49 (22.4%)45/49 (91.8%)
Carfilzomib and Dexamethasone (Kd)2/52 (3.8%)20/52 (38.5%)42/52 (80.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
PneumoniaInfections and infestations2/493/52
Lower respiratory tract infectionInfections and infestations2/491/52
Cardiac failureCardiac disorders0/492/52
Acute kidney injuryRenal and urinary disorders0/492/52
Acute cardiac eventCardiac disorders1/490/52
Visual impairmentEye disorders1/490/52
DiarrhoeaGastrointestinal disorders1/490/52
Neutropenic colitisGastrointestinal disorders1/490/52
FatigueGeneral disorders1/490/52
PyrexiaGeneral disorders1/490/52
Most frequent other events
Showing 10 of 32
Most frequent other events
EventCarfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)
CoughRespiratory, thoracic and mediastinal disorders13/4922/52
AnaemiaBlood and lymphatic system disorders8/4919/52
PyrexiaGeneral disorders8/4914/52
ThrombocytopeniaBlood and lymphatic system disorders9/4912/52
DiarrhoeaGastrointestinal disorders9/4912/52
HypertensionVascular disorders9/498/52
AstheniaGeneral disorders5/499/52
FatigueGeneral disorders3/499/52
HyperglycaemiaMetabolism and nutrition disorders5/499/52
DyspnoeaRespiratory, thoracic and mediastinal disorders2/498/52

Baseline characteristics

Measured in the full analysis set, which included all enrolled participants.

Age, Continuous
Age, Continuous(years)Carfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)Total
Mean57.2 ± 8.261.9 ± 9.959.6 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)Total
Female171532
Male323769
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)Total
Hispanic or Latino000
Not Hispanic or Latino4952101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Carfilzomib, Lenalidomide and Dexamethasone (KRd)Carfilzomib and Dexamethasone (Kd)Total
American Indian or Alaska Native000
Asian4952101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

17 sites
  • Yashoda Hospital
    Hyderabad, Andhra Pradesh 500 082, India
  • Apollo Hospital
    Hyderabad, Andhra Pradesh 500033, India
  • M S Ramaiah Memorial Hospital
    Bangalore, Karnataka 560054, India
  • K L E S Dr Prabhakar Kore Hospital and Medical Research Centre
    Belagavi, Karnataka 590010, India
  • Cytecare Cancer Hospitals
    Bengaluru, Karnataka 560064, India
  • Aster Medcity
    Kochi, Kerala 682027, India
  • Government Medical College
    Kozhikode, Kerala 673008, India
  • Tata Memorial Hospital
    Mumbai, Maharashtra 400 012, India
  • Mumbai Oncocare Center
    Mumbai, Maharashtra 400 056, India
  • Navsanjeevani Hospital
    Nashik, Maharashtra 422 002, India
  • Heath Care Group Manavata Cancer Centre
    Nashik, Maharashtra 422 004, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharashtra 411004, India
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Puducherry, Puducherry 605 006, India
  • Cancer Institute WIA
    Chennai, Tamil Nadu 600020, India
  • Thangam Cancer Centre
    Namakkal, Tamil Nadu 637001, India
  • Valentis Cancer Hospital
    Meerut, Uttar Pradesh 250001, India
  • Netaji Subhash Chandra Bose Cancer Research Institute
    Kolkata, West Bengal 700 094, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Mar 2023, 42 months.

Results were first posted in Jan 2024, 9 months after primary completion.

Of 28 phase 4 interventional studies under Multiple Myeloma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 57. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2019
First posted
May 2, 2019
StartActual
Sep 16, 2019
Primary completionActual
Mar 23, 2023
CompletionActual
Jun 27, 2025
Results first posted
Jan 2, 2024
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03934684
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 2, 2019
Start date
Sep 16, 2019
Primary completion
Mar 23, 2023
Completion
Jun 27, 2025
Results posted
Jan 2, 2024
Last update
May 11, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carfilzomib · Dexamethasone · Lenalidomide

Start the discussion